Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Tove, Wästerlid"'
Autor:
Tove Wästerlid, Caroline E. Dietrich, Anna Oksanen, Linn Deleskog Spångberg, Björn E Wahlin, Gunilla Enblad, Per‐Ola Andersson, Eva Kimby, Karin E. Smedby
Publikováno v:
eJHaem, Vol 5, Iss 3, Pp 516-526 (2024)
Abstract Follicular lymphoma (FL) is a clinically heterogeneous disease. The need for treatment, treatment sequencing, number of treatment lines, and its association with survival have not been described in a population‐based setting. We identified
Externí odkaz:
https://doaj.org/article/31ddbf491bfe4c60a132be0f3bbccbd9
Autor:
Qianwei Liu, Karin Ekström Smedby, Huiwen Xue, Tove Wästerlid, Jiong Li, Fang Fang, Xinyuan Liu
Publikováno v:
EClinicalMedicine, Vol 74, Iss , Pp 102753- (2024)
Summary: Background: Pulmonary embolism causes a substantial burden of morbidity and mortality. Although there are several well-established risk factors for pulmonary embolism, a substantial proportion of cases cannot be attributed to provoked or kno
Externí odkaz:
https://doaj.org/article/f945f53e9fdc481b92bbf99364eb0103
Autor:
Karin Ekström Smedby, Sandra Eloranta, Tove Wästerlid, Victor Falini, Urban Jerlström, Fredrik Ellin, Karin Papworth, Johanna Westerberg, Catharina Lewerin, Per-Ola Andersson, Hallgerdur Lind Kristjansdottir, Lena Brandefors, Charlott Mörth, Karin Hallén, Nevzeta Kuric, Amal Abu Sabaa, Björn E. Wahlin, Daniel Molin, Gunilla Enblad, Ann-Sofi Hörstedt, Mats Jerkeman, Ingrid Glimelius
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: The Swedish Lymphoma Register (SLR) was initiated in the year 2000 with the aim to monitor quality of care in diagnostics, treatment and outcome of all lymphomas diagnosed nationally among adults. Here, we present the first sy
Externí odkaz:
https://doaj.org/article/7ee070d713af42f29167468a2f959abb
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 46, Iss , Pp 100785- (2024)
Background and purpose: The role of radiotherapy (RT) in lymphoma is constantly refined with the advent of novel treatments. However, RT is still an effective treatment and tolerability is high. Therefore, we aimed to describe the use of RT in primar
Externí odkaz:
https://doaj.org/article/86c6266f450540e383cfd01acc150b1f
Autor:
Sara Ekberg, Daniel Molin, Simon Pahnke, Fanny Bergström, Elsa Brånvall, Karin E. Smedby, Tove Wästerlid
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background & purpose: The COVID-19 pandemic posed a large challenge for healthcare systems across the world. Comprehensive data on the impact of the COVID-19 pandemic on incidence and mortality in lymphoma are lacking. Patients/methods: Using data f
Externí odkaz:
https://doaj.org/article/d2dd94c28a13422f9958d66fbdcd4af7
Autor:
Zahra Haider, Tove Wästerlid, Linn Deleskog Spångberg, Leily Rabbani, Cecilia Jylhä, Birna Thorvaldsdottir, Aron Skaftason, Hero Nikdin Awier, Aleksandra Krstic, Anna Gellerbring, Anna Lyander, Moa Hägglund, Ashwini Jeggari, Georgios Rassidakis, Kristina Sonnevi, Birgitta Sander, Richard Rosenquist, Emma Tham, Karin E. Smedby
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionAnalyzing liquid biopsies for tumor-specific aberrations can facilitate detection of measurable residual disease (MRD) during treatment and at follow-up. In this study, we assessed the clinical potential of using whole-genome sequencing (
Externí odkaz:
https://doaj.org/article/d9f81232bcd743c6ba826c8c6e6a8a2b
Autor:
Caroline E. Weibull, Tove Wästerlid, Björn Engelbrekt Wahlin, Per-Ola Andersson, Sara Ekberg, Sandra Lockmer, Gunilla Enblad, Michael J. Crowther, Eva Kimby, Karin E. Smedby
Publikováno v:
HemaSphere, Vol 7, Iss 3, p e838 (2023)
In follicular lymphoma (FL), progression of disease ≤24 months (POD24) has emerged as an important prognostic marker for overall survival (OS). We aimed to investigate survival more broadly by timing of progression and treatment in a national popul
Externí odkaz:
https://doaj.org/article/39d5fc75e5ef43388f6aaf43bf4eb9e6
Autor:
Kristina Sonnevi, Maria Ljungqvist, Jóel Kristinn Jóelsson, Sara Harrysson, Tove Wästerlid, Per Bernell, Björn Engelbrekt Wahlin
Publikováno v:
eJHaem, Vol 2, Iss 4, Pp 774-784 (2021)
Abstract Patients with high‐risk aggressive B‐cell lymphoma exhibit poor survival after R‐CHOP. More intensive regimens yield higher rates of remission but also of complication. We investigated all 401 patients
Externí odkaz:
https://doaj.org/article/5185da9e7f6e45189ee1703f58593a70
Autor:
Núria Rodríguez Ruiz, Sulaf Abd Own, Karin Ekström Smedby, Sandra Eloranta, Sabine Koch, Tove Wästerlid, Aleksandra Krstic, Magnus Boman
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThe increasing amount of molecular data and knowledge about genomic alterations from next-generation sequencing processes together allow for a greater understanding of individual patients, thereby advancing precision medicine. Molecular tum
Externí odkaz:
https://doaj.org/article/95dcbd805ef646bea270c89adfaf3940
Autor:
Jeanette Lundin, Tom A. Mulder, Magdalena Kättström, Tove Wästerlid, Anders Uddevik, Håkan Mellstedt, Kia Heimersson, Lotta Hansson, Marzia Palma, Anders Österborg
Publikováno v:
eJHaem, Vol 2, Iss 3, Pp 525-529 (2021)
Abstract Ibrutinib is used continuously in CLL. This phase 1b/2 study interim analysis explored on‐off‐repeat dosing to reduce toxicity. After 12 months, 16/22 patients (73%) remained in first off‐phase irrespective if initial CR/PR or TP53 abe
Externí odkaz:
https://doaj.org/article/7f328d6a737444259549a86a1865a7f1